<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601365</url>
  </required_header>
  <id_info>
    <org_study_id>PSHCH0001</org_study_id>
    <nct_id>NCT02601365</nct_id>
  </id_info>
  <brief_title>Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia</brief_title>
  <acronym>iGRASP</acronym>
  <official_title>A Phase I Study of Inhaled GM-CSF in the Treatment of Respiratory Virus-associated Severe Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety and efficacy of the administration of inhaled GM-CSF
      to children with respiratory virus-associated pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute respiratory failure from respiratory viruses including influenza A virus and
      respiratory syncytial virus are a common cause of pediatric intensive care unit (PICU)
      admissions and the requirement of initiation of mechanical ventilation. In a subset of
      subjects who are difficult to identify based on patient characteristics, worsening lung
      disease, or pneumonia, develops and these subjects progress to pediatric acute respiratory
      distress syndrome (PARDS). This can result in prolonged PICU stay, significant morbidity, and
      in some cases, mortality. The overarching goal of this project is to improve the outcomes for
      these patients with PARDS secondary to respiratory virus infections. Research suggests that
      granulocyte-macrophage colony stimulating factor (GM-CSF), a cytokine produced by many cell
      types in the body, has added significance in the lung and may be an important factor in the
      resolution of lung inflammation, and may be suppressed by respiratory viruses. This
      GM-CSF-deficient environment may be an important trigger of lung dysfunction; therefore,
      replenishment of the lung with exogenous GM-CSF has the potential to be extremely beneficial.
      In this phase I dose escalation clinical study we propose to investigate the safety and
      efficacy of the administration of inhaled GM-CSF (iGM-CSF) to children with respiratory
      virus-associated PARDS.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse effects of inhaled GM-CSF</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygenation</measure>
    <time_frame>28 days</time_frame>
    <description>Measured using the oxygen saturation index (OSI) or oxygenation index (OI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Ventilator free days at 28 days after study enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanistic Biomarkers</measure>
    <time_frame>28 days</time_frame>
    <description>Broncho-alveolar lavage fluid proteins and cells will be measured</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pediatric Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mcg/m2 daily of iGM-CSF for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mcg/m2 daily of iGM-CSF for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125mcg/m2 daily of iGM-CSF for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250mcg/m2 daily (divided BID) of iGM-CSF for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled GM-CSF (sargramostim)</intervention_name>
    <description>GM-CSF will be administered over 4h via a nebulizer</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Leukine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Patient must be admitted to the Penn State Hershey Children's Pediatric Intensive
             Care Unit (PICU) 2. Patient must be invasively mechanically ventilated 3. Patients
             must meet criteria for pediatric acute respiratory distress syndrome (PARDS) as
             outlined by the Pediatric Acute Lung Injury Consensus Conference (PALICC):

               -  Acute onset

               -  Within 7 days of a known clinical insult

               -  Respiratory failure not fully explained by cardiac failure or fluid overload

               -  Chest imaging findings of a new infiltrate(s) consistent with acute pulmonary
                  parenchymal disease

               -  Oxygen saturation index (OSI) â‰¥ 5 4. Patients must have a respiratory virus panel
                  that is positive for a virus listed below:

               -  Influenza A or B virus

               -  Respiratory syncytial virus (RSV)

               -  Coronavirus

               -  Adenovirus

               -  Rhinovirus

               -  Parainfluenza virus

               -  Human metapneumovirus

        Exclusion Criteria:

          -  1. Age &lt; 2months or &gt; 18 years 2. Clinical diagnosis of congestive heart failure
             and/or pulmonary capillary wedge pressure &gt; 15mmHg or uncorrected congenital heart
             disease 3. Pre-existing limitations on care options (Do Not Resuscitate orders, etc.)
             4. Patients with impending death from another disease process 5. Patients with known
             malignancy 6. Patients who are known to be pregnant 7. Patients with unresolved other
             organ failure at time of possible randomization:

               -  Refractory hypotension

               -  Persistent cardiac arrhythmia

               -  Metabolic acidosis &gt; -10 mEq/L for more than 2 hours

               -  Hyperkalemia - serum potassium &gt; 6.5 plus widening of QRS complex on ECG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Thomas NJ, Shaffer ML, Willson DF, Shih MC, Curley MA. Defining acute lung disease in children with the oxygenation saturation index. Pediatr Crit Care Med. 2010 Jan;11(1):12-7. doi: 10.1097/PCC.0b013e3181b0653d.</citation>
    <PMID>19561556</PMID>
  </reference>
  <reference>
    <citation>Cakarova L, Marsh LM, Wilhelm J, Mayer K, Grimminger F, Seeger W, Lohmeyer J, Herold S. Macrophage tumor necrosis factor-alpha induces epithelial expression of granulocyte-macrophage colony-stimulating factor: impact on alveolar epithelial repair. Am J Respir Crit Care Med. 2009 Sep 15;180(6):521-32. doi: 10.1164/rccm.200812-1837OC. Epub 2009 Jul 9.</citation>
    <PMID>19590023</PMID>
  </reference>
  <reference>
    <citation>Huang FF, Barnes PF, Feng Y, Donis R, Chroneos ZC, Idell S, Allen T, Perez DR, Whitsett JA, Dunussi-Joannopoulos K, Shams H. GM-CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care Med. 2011 Jul 15;184(2):259-68. doi: 10.1164/rccm.201012-2036OC. Epub 2011 Apr 7.</citation>
    <PMID>21474645</PMID>
  </reference>
  <reference>
    <citation>Sever-Chroneos Z, Murthy A, Davis J, Florence JM, Kurdowska A, Krupa A, Tichelaar JW, White MR, Hartshorn KL, Kobzik L, Whitsett JA, Chroneos ZC. GM-CSF modulates pulmonary resistance to influenza A infection. Antiviral Res. 2011 Nov;92(2):319-28. doi: 10.1016/j.antiviral.2011.08.022. Epub 2011 Sep 8.</citation>
    <PMID>21925209</PMID>
  </reference>
  <reference>
    <citation>Ghoneim HE, Thomas PG, McCullers JA. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol. 2013 Aug 1;191(3):1250-9. doi: 10.4049/jimmunol.1300014. Epub 2013 Jun 26.</citation>
    <PMID>23804714</PMID>
  </reference>
  <reference>
    <citation>Steinwede K, Tempelhof O, Bolte K, Maus R, Bohling J, Ueberberg B, LÃ¤nger F, Christman JW, Paton JC, Ask K, Maharaj S, Kolb M, Gauldie J, Welte T, Maus UA. Local delivery of GM-CSF protects mice from lethal pneumococcal pneumonia. J Immunol. 2011 Nov 15;187(10):5346-56. doi: 10.4049/jimmunol.1101413. Epub 2011 Oct 14.</citation>
    <PMID>22003204</PMID>
  </reference>
  <reference>
    <citation>Unkel B, Hoegner K, Clausen BE, Lewe-Schlosser P, Bodner J, Gattenloehner S, JanÃŸen H, Seeger W, Lohmeyer J, Herold S. Alveolar epithelial cells orchestrate DC function in murine viral pneumonia. J Clin Invest. 2012 Oct;122(10):3652-64. doi: 10.1172/JCI62139. Epub 2012 Sep 10.</citation>
    <PMID>22996662</PMID>
  </reference>
  <reference>
    <citation>Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, Carcillo JA. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011 Mar;37(3):525-32. doi: 10.1007/s00134-010-2088-x. Epub 2010 Dec 10.</citation>
    <PMID>21153402</PMID>
  </reference>
  <reference>
    <citation>Paine R 3rd, Standiford TJ, Dechert RE, Moss M, Martin GS, Rosenberg AL, Thannickal VJ, Burnham EL, Brown MB, Hyzy RC. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med. 2012 Jan;40(1):90-7. doi: 10.1097/CCM.0b013e31822d7bf0.</citation>
    <PMID>21926600</PMID>
  </reference>
  <reference>
    <citation>Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell BC. Therapy options in pulmonary alveolar proteinosis. Ther Adv Respir Dis. 2010 Aug;4(4):239-48. doi: 10.1177/1753465810378023. Epub 2010 Jul 20. Review.</citation>
    <PMID>20647242</PMID>
  </reference>
  <reference>
    <citation>Trapnell BC, Carey BC, Uchida K, Suzuki T. Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages. Curr Opin Immunol. 2009 Oct;21(5):514-21. doi: 10.1016/j.coi.2009.09.004. Epub 2009 Sep 30. Review.</citation>
    <PMID>19796925</PMID>
  </reference>
  <reference>
    <citation>Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ishii H, Yokoba M, Tanaka N, Yamaguchi E, Eda R, Tsuchihashi Y, Morimoto K, Akira M, Terada M, Otsuka J, Ebina M, Kaneko C, Nukiwa T, Krischer JP, Akazawa K, Nakata K. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2010 Jun 15;181(12):1345-54. doi: 10.1164/rccm.200906-0978OC. Epub 2010 Feb 18.</citation>
    <PMID>20167854</PMID>
  </reference>
  <reference>
    <citation>Herold S, Hoegner K, VadÃ¡sz I, Gessler T, Wilhelm J, Mayer K, Morty RE, Walmrath HD, Seeger W, Lohmeyer J. Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am J Respir Crit Care Med. 2014 Mar 1;189(5):609-11. doi: 10.1164/rccm.201311-2041LE.</citation>
    <PMID>24579839</PMID>
  </reference>
  <reference>
    <citation>Papiris SA, Tsirigotis P, Kolilekas L, Papadaki G, Papaioannou AI, Triantafillidou C, Papaporfyriou A, Karakatsani A, Kagouridis K, Griese M, Manali ED. Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose. Clin Drug Investig. 2014 Aug;34(8):553-64. doi: 10.1007/s40261-014-0208-z.</citation>
    <PMID>24890235</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>September 18, 2016</last_update_submitted>
  <last_update_submitted_qc>September 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>E. Scott Halstead, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

